Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

Non-specific immunotherapy has been for a long time a standard treatment option for patients with metastatic renal cell carcinoma but was redeemed by specific targeted molecular therapies, namely the VEGF and mTOR inhibitors. After moving treatment for mRCC to specific molecular agents with a well-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedke, Jens, Gouttefangeas, Cécile, Singh-Jasuja, Harpreet, Stevanović, Stefan, Behnes, Carl-Ludwig, Stenzl, Arnulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Topic Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901931/
https://www.ncbi.nlm.nih.gov/pubmed/23404195
http://dx.doi.org/10.1007/s00345-013-1033-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901931/
https://www.ncbi.nlm.nih.gov/pubmed/23404195
http://dx.doi.org/10.1007/s00345-013-1033-3

Ejemplares similares